Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 201 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv201
  2. Study sites revised (17)v200
  3. Study sites revised (17)v199
  4. Study completion pushed from Apr 24, 2026 to Apr 24, 2027v198
  5. 37 versions Re-verified since Aug 20, 2025, no change to tracked fieldsv161-v197
Show 9 earlier versionsHide 9 earlier versions
  1. Study completion date: Apr 24, 2025 to Apr 24, 2026v160
  2. 2 versions Re-verified since Aug 21, 2024, no change to tracked fieldsv158-v159
  3. Study sites revised (17)v157
  4. Study completion date: Apr 11, 2024 to Apr 24, 2025v156
  5. 4 versions Re-verified since Aug 24, 2023, no change to tracked fieldsv152-v155
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.
Trial Details
NCT Number NCT00268385
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Related terms Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma, Oligodendroglioma
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov